Top stories from Retina World Congress

The Retina World Congress was held in Fort Lauderdale, Florida, from March 21 to 24. Here are the top five most-read articles or most-watched video interviews from Healio.com/OSN’s live meeting coverage.

 

At 1 year, aflibercept injections did not impact CNV conversion rates

Patients with intermediate age-related macular degeneration treated with intravitreal aflibercept injections did not experience improved rates of non-conversion to neovascular age-related macular degeneration after 12 months of treatment. Read more.

 

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients

Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, discusses first results of a phase 2a study of ALK4290 (Alkahest), now known as AKST4290, for the treatment of patients with newly diagnosed wet age-related macular degeneration. Watch here.

 

Social cost of retinal blindness in US will be billions of dollars by 2020

The direct, indirect and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy is estimated to cost the U.S. approximately $21 billion by 2020. Read more.

 

Plasma rich in growth factors showed success in macular hole closure

The use of plasma rich in growth factors for recurrent macular hole closures in a pilot study showed success in two patients over a 12-month follow-up period. Read more.

 

Suprachoroidal drug delivery shows benefits for DME treatment

Suprachoroidal drug delivery is a novel approach that targets posterior tissues, minimizes exposures to the anterior segment and has shown benefits as a diabetic macular edema treatment in early studies. Read more.

The Retina World Congress was held in Fort Lauderdale, Florida, from March 21 to 24. Here are the top five most-read articles or most-watched video interviews from Healio.com/OSN’s live meeting coverage.

 

At 1 year, aflibercept injections did not impact CNV conversion rates

Patients with intermediate age-related macular degeneration treated with intravitreal aflibercept injections did not experience improved rates of non-conversion to neovascular age-related macular degeneration after 12 months of treatment. Read more.

 

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients

Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, discusses first results of a phase 2a study of ALK4290 (Alkahest), now known as AKST4290, for the treatment of patients with newly diagnosed wet age-related macular degeneration. Watch here.

 

Social cost of retinal blindness in US will be billions of dollars by 2020

The direct, indirect and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy is estimated to cost the U.S. approximately $21 billion by 2020. Read more.

 

Plasma rich in growth factors showed success in macular hole closure

The use of plasma rich in growth factors for recurrent macular hole closures in a pilot study showed success in two patients over a 12-month follow-up period. Read more.

 

Suprachoroidal drug delivery shows benefits for DME treatment

Suprachoroidal drug delivery is a novel approach that targets posterior tissues, minimizes exposures to the anterior segment and has shown benefits as a diabetic macular edema treatment in early studies. Read more.